Immune Acquires Worldwide Rights

Immune Acquires Worldwide Rights
Accelerates Development for the Treatment
Psoriasis and Atopic Dermatitis

Los Angeles, January 14, 2106 - StockWatchIndex (SWI) announced today that Immune Pharmaceutical, a clinical-stage biopharmaceutical company, after reviewing new efficacy data for a novel topical nano-capsule formulation of cyclosporine, has acquired worldwide development and licensing rights for the treatment of Psoriasis and Atopic Dermatitis.

As we had reported only a few days ago, in 2015, Immune made important progress with its lead drug candidate, Bertilimumab, receiving clearance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application, which allowed the company to include U.S. patients in its Phase II clinical trial in bullous pemphigoid, an orphan auto-immune disease of the skin.

Following the review of new efficacy data, Immune has now entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd, an Israeli nanotechnology drug delivery company, for a novel topical nano-capsule formulation of cyclosporine, also known as "cyclosporine-A" or "CsA".

According to the Chief Medical Officer of Immune, Monica Luchi, M.D., Oral cyclosporine is a potent immunosuppressive drug, known to reduce the activity of the immune system by interfering with T-cells and has revolutionized transplantation medicine. Its use in dermatology has been limited to severe cases of psoriasis and atopic dermatitis, because of significant systemic toxicity. In a validated human skin model of atopic dermatitis, a novel topical nano-capsule formulation of cyclosporine A demonstrated comparable efficacy to a high potency topical corticosteroid. Immune believes that this product candidate could provide an important therapeutic alternative for millions of patients with chronic inflammatory skin disorders such as moderate atopic dermatitis and psoriasis. The company intends to accelerate the development of this product candidate under the abbreviated 505(b)(2) drug development pathway permitted by the U.S. Food and Drug Administration.

Professor Simon Benita, the former Director of the Institute for Drug Research and Head of the School of Pharmacy at the Hebrew University of Jerusalem believes that the collaboration with Immune will leverage his nanotechnology expertise and advance this novel product candidate into the clinic. This topical nano-capsule formulation of cyclosporine incorporates a patented technology invented by  Professor Benita, who has pioneered a nano-drug delivery platform for improving the absorption of poorly absorbed drugs. This product candidate -topical cyclosporine nano-capsules- builds on Immune's focused Immuno-dermatology franchise.

For the text of the full company press release, please visit For further information contact Immune Pharmaceuticals Inc., Anna Baran, Director, Corporate Affairs, Tel: 646-561-8010,

    SWI Research Report

Unique Buying Opportunity
We reiterate that the advancement in Immune's product development, the FDA's approval for the Investigational New Drug (IND) application, the acquisition of the worldwide rights for the Treatment of Psoriasis and Atopic Dermatitis, the company's plans for the expansion of its clinical trial centers and the engagement of a new, highly experienced management team should result in reaching the mile stones that Immune has set for itself for 2016 and that investors expect.

Immune Pharmaceutical Video on Small Cap Nation

Please visit our sites and
We would appreciate if you could pass our newsletter on to your friends and
colleagues. We always appreciate your feedback and comments.
About SWI
SWI is a leading edge PR, Information Marketing and Research firm with a highly frequented web site, its "Rise Above The Noise" newsletter and SWI Research site published for the investment community. These services provide subscribers with information and research on new, often undiscovered, but promising public companies. The QuickPicks section on the SWI site represents the consolidated opinions of carefully selected financial analysts and credible Wall Street firms that we respect and frequently sample. Our weekly SWI QuickPicks  Ratings Report keeps subscribers informed about newly SWI initiated stocks and potential upgrades and downgrades in the QuickPicks section. We are not being compensated by the companies for the stocks in the QuickPicks section and do not necessarily hold positions in any of these stocks.. SWI's  "Portfolio Performance Report" periodically reports about the performance of the stocks that we have purchased for our portfolio, typically hold long and may be trading without notice.  Please do not miss the wealth of frequently updated news, research reports and other valuable information elsewhere on SWI, especially for the stocks on our WatchIndex page. Watch a full range of CEO and analyst interviews on our Strategic Partner site  
Google +

StockWatchIndex (SWI) is not a registered investment adviser and makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise) of the information provided in the publications for its Stock Watch List, on its web sites or its newsletter. The provided information is not to be construed as personal financial advice, or a solicitation to buy or sell stock. Some information has been generated by what SWI deems to be reliable third party entities, or the companies' themselves, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrants any results from use of the information. We have contracted with some of the companies we present on SWI or in the SWI Newsletter as public relations consultants to keep the market and especially our subscribers informed about the companies and may have been compensated in cash and/or stock and stock options, which may be considered a potential conflict of interest. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in its Stock Watch List or in any of its other publications. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. StockWatchIndex expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. The included information is subject to change without notice.

Copyright © 2016 DynamicMarketConcepts, All rights reserved.

unsubscribe from this list    update subscription preferences 

Email Marketing Powered by Mailchimp